The use of ondansetron in psychiatry: An educational article and expert opinion
Abstract
Neuroleptics are anti-psychotics medications that are used in a variety of neuropsychiatric disorders including schizophrenia, anxiety, Tourette syndrome, autism, and mental retardation. The first and second generations of neuroleptics are dopamine 2 receptor blocker and the first generation agents are associated with significant risk of the occurrence of extra-pyramidal side effects in effective doses. Despite the emergence of several generations of neuroleptics, the disadvantages of the relatively high incidence of side effects and treatment resistance continued as challenging problems 1-6.
It has been suggested that these problems may be solved with use of adjunctive therapies that help in improving responsiveness and reduce the possibility of the occurrence of side effects. The aim of this paper is to provide a relevant educational overview of ondansetron research progress in the field of psychiatry.
Conclusion: The current expert opinion suggests that ondansetron has the potential to be the agent which can help in solving the problem associated with use of neuroleptics including the possibility of the occurrence of side effects and treatment resistance. There is preliminary evidence suggesting that ondansetron can be used as an adjunctive therapy in a variety of neuropsychiatric disorders including schizophrenia, Tourette syndrome, and obsessive-compulsive disorder.
Keywords: Ondansetron, neuropsychiatric disorders, expert opinion.
Keywords:
Ondansetron, neuropsychiatric disorders, expert opinionDOI
https://doi.org/10.22270/jddt.v13i8.5927References
-Al-Mosawi AJ. A Case of Childhood Schizophrenia and a Unique Experience with Medical Treatments and Insight Psychotherapy. International Journal of Neurobiology (ISSN: 2694-3972) 23April, 2022; 4(2):1-3. Doi: https://doi.org/10.36266/IJN/145
-Al-Mosawi AJ. Gilles De La Tourette Syndrome: A Case and A Brief Review of the Early Documentation of the Syndrome in the Literature. International Journal of Psychiatry (ISSN: 2475-5435) 2020 Nov 26; 5(3):1-4.
-Al-Mosawi AJ.Pervasive developmental disorders in Iraqi children. Journal of Psychiatry Research Reviews & Reports 2019 Sep 11; 1(1):1-8. Doi: 10.5281/zenodo. 4007395. https://doi.org/10.47363/JPSRR/2019(1)102
-Al-Mosawi AJ. Treatment of a boy with idiopathic mental retardation: From uneducable to educable. SunKrist Clinical and Medical Case Reports Journal 2020 August 17; 2 (1):1-6. Scmcrj-v2-1007. https://doi.org/10.46940/scmcrj.02.1007
-Al-Mosawi AJ. The pattern of mental retardation in Iraqi children.1st ed., Saarbrücken; LAP Lambert Academic Publishing: 2019 (ISBN: 978-613-9-47350-2).
-Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry 2000 Feb; 157(2):287-9. https://doi.org/10.1176/appi.ajp.157.2.287
-Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of Ondansetron on memory in schizophrenic patients. Brain Res Bull 2005 Apr 30; 65(4):291-5. https://doi.org/10.1016/j.brainresbull.2003.09.022
-Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res 2006 Dec; 88(1-3):102-10. https://doi.org/10.1016/j.schres.2006.07.010
-Kulkarni J, Thomas N, Hudaib AR, Gavrilidis E, Gurvich C. Ondansetron : a promising adjunctive treatment for persistent schizophrenia. J Psychopharmacol 2018 Nov; 32(11):1204-1211. https://doi.org/10.1177/0269881118798608
-Faris PL, Kim SW, Meller WH, Goodale RL, Oakman SA, Hofbauer RD, Marshall AM, Daughters RS, Banerjee-Stevens D, Eckert ED, Hartman BK. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000 Mar 4; 355(9206):792-797. https://doi.org/10.1016/S0140-6736(99)09062-5
-Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry 2003 Sep; 64(9):1025-30. https://doi.org/10.4088/JCP.v64n0907
-Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009 Dec; 23(12):1047-55. https://doi.org/10.2165/11530240-000000000-00000
-Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol 2014 Mar; 24(3):375-80. https://doi.org/10.1016/j.euroneuro.2013.12.003
-Toren P, Laor N, Cohen DJ, Wolmer L, Weizman A. Ondansetron treatment in patients with Tourette's syndrome. Int Clin Psychopharmacol 1999 Nov; 14(6):373-6. https://doi.org/10.1097/00004850-199911000-00008
-Toren P, Weizman A, Ratner S, Cohen D, Laor N. Ondansetron treatment in Tourette's disorder: a 3-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2005 Apr; 66(4):499-503. https://doi.org/10.4088/JCP.v66n0413
Published
Abstract Display: 459 
PDF Downloads: 613 PDF Downloads: 62 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.